Clinical

Suboptimal statin response predicts future risk


 

Background: Rates of LDL-C reduction with statin therapy vary based on biological and genetic factors, as well as adherence. In a general primary prevention population at cardiovascular risk, little is known about the extent of this variability or its impact on outcomes.


Study design: Prospective cohort study.

Setting: Primary care practices in England and Wales.

Synopsis: Across a cohort of 183,213 patients, 51.2% had a suboptimal response, defined as a less than 40% proportional reduction in LDL-C. During more than 1 million ­person-years of follow-up, suboptimal statin response at 2 years was associated with a 20% higher hazard ratio for incident cardiovascular disease.Bottom line: Half of patients do not have a sufficient response to statins, with higher attendant future risk.

Citation: Akyea RK et al. Suboptimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart. 2019 Apr 15;0:1-7. doi: 10.1136/heartjnl-2018-314253.

Dr. Anderson is chief, hospital medicine section, and deputy chief, medicine service, at the Veterans Affairs Eastern Colorado Health Care System, Aurora.

Recommended Reading

Mortality differs by LVEF between women and men
The Hospitalist
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
The Hospitalist
Preventing arrhythmias and QTc prolongation in COVID-19 patients on psychotropics
The Hospitalist
CVD risk continues to fall down to systolic BP of 90 mm HG
The Hospitalist
Cost of preventable adult hospital stays topped $33 billion in 2017
The Hospitalist
ED visits for life-threatening conditions declined early in COVID-19 pandemic
The Hospitalist
VA readmissions program not linked to increased death
The Hospitalist
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
The Hospitalist
COVID-19: ‘dramatic’ surge in out-of-hospital cardiac arrests in NYC
The Hospitalist
How to reboot elective CV procedures after COVID-19 lockdown
The Hospitalist
   Comments ()